Article info

PDF
Short Report
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium

Authors

  1. Correspondence to Dr Encarna Gómez García, Department of Clinical Genetics Maastricht University Medical Centre, Maastricht 6202 AZ, The Netherlands; encarna.gomezgarcia{at}mumc.nl
View Full Text

Citation

Moghadasi S, Meeks HD, Vreeswijk MP, et al
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium

Publication history

  • Received 24 January 2017
  • Revised 11 April 2017
  • Accepted 17 April 2017
  • Published online 10 May 2017.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.